Scribe notes down IPO ambition to fund lipid-lowering genetic meds through clinical trials
From the article
Scribe Therapeutics is the latest biotech to prepare a public listing, as the company looks to propel its lipid-lowering medicines through clinical trials.
Continue reading on Fierce BiotechYou might also wanna read
CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Bars·2d ago
CRISPR’s next act: the companies editing the epigenome to treat disease
go.nature.com·7d ago
BioLineRx, Hemispherian announces new preclinical data on GLIX1, PARP inhibitor
thefly.com·14h ago
Obesity biotech Kalohexis files confidential IPO
pharmaphorum·1d ago
Single Infusion of Gene-Editing Therapy VERVE-102 Shows Promise for Inherited High Cholesterol
An experimental gene-editing therapy called VERVE-102, developed by Verve Therapeutics (a subsidiary of Eli Lilly), shows promise in treatin
discovermagazine.com·1mo ago
Remix does reverse merger with Passage Bio for mRNA degrader
endpoints.news·13d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.